Nova Scotia Health’s solid tumour clinical trials team at the Atlantic Clinical Cancer Research Unit (ACCRU) has become the first site in the world to launch—and the first to enroll a patient in—a major international clinical trial led by AstraZeneca.
The Artemide Biliary 02 study is evaluating a potential new treatment for biliary tract cancer, a rare and very aggressive cancer with limited options for patients. Because this disease is so uncommon, it’s often challenging to start trials quickly or find eligible participants, which makes Nova Scotia’s early activation especially meaningful.
The trial is led locally by Dr. Ravi Ramjeesingh, Medical Oncologist with Nova Scotia Health and the Medical Director with ACCRU, with clinical support from Dr. Abdul Farooq, Medical Oncologist with Nova Scotia Health.
What this milestone shows:
- Nova Scotia is becoming a place where important cancer research can happen—and happen quickly.
- Patients here are gaining earlier access to promising new treatments.
- And our teams are contributing to answers that could help patients around the world.
Stay tuned for more information!
